Oncotelic Therapeutics, Inc. (OTLC): M&A transaction — Oncotelic completes merger transferring patent portfolio to Lunai for $20M Series B Preferred stock

Oncotelic Therapeutics, Inc.

Oncotelic contributed patent portfolio to Neurobridge Holdings, which merged into Lunai subsidiary; Oncotelic received 5 Series B shares (stated value $12.5M).
Shares convertible at $1.50/common, but conversion requires stockholder approval; no conversion allowed before approval.
Oncotelic retains perpetual, exclusive, royalty-free license to use the patents except for Biodefense and Alzheimer's fields.
Oncotelic agreed to issue 10% of fully diluted shares to Autotelic upon uplisting in exchange for assets including peptide Y, PTH, insulin formulations.
All transactions completed May 1, 2026; no cash exchanged.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.4

Oncotelic Therapeutics, Inc. issued a number of shares of Common Stock equal to ten percent (10%) of the fully diluted outstanding shares of common stock to Autotelic, Inc..

Security: common stock
Shares: a number of shares of Common Stock equal to ten percent (10%) of the fully diluted outstanding shares
Purchaser: Autotelic, Inc.

Exact text from the filing

In connection with the Asset Transfer Agreement described in Item 1.01 above, the Company has agreed to issue to Autotelic, Inc. a number of shares of Common Stock equal to ten percent (10%) of the fully diluted outstanding shares of Oncotelic Therapeutics, Inc. with the issuance conditioned on an uplisting of its capital stock to NYSE/NASDAQ.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Oncotelic Therapeutics, Inc. completed an acquisition involving Lunai Bioworks, Inc. for aggregate stated value of $20,000,000 (closed 2026-05-01).

Action: acquisition
Counterparty: Lunai Bioworks, Inc.
Consideration: aggregate stated value of $20,000,000
Closing: 2026-05-01

Exact text from the filing

greement and Plan of Merger (the “Merger Agreement”) with Lunai Bioworks, Inc., a Delaware corporation (“Lunai”), Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Oncotelic Therapeutics, Inc. entered into Asset Transfer Agreement with Autotelic Inc. (effective 2026-04-30).

Action: entry
Agreement: asset purchase
Counterparty: Autotelic Inc.
Effective: 2026-04-30

Exact text from the filing

On April 30, 2026, the Company and Autotelic Inc. (“Autotelic”) entered into an asset transfer agreement (the “Asset Transfer Agreement”)

View on SEC.gov

Browse all equity issuances →

Oncotelic Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-021306

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.